昭衍新药
(603127)
| 流通市值：238.70亿 | | | 总市值：283.75亿 |
| 流通股本：6.30亿 | | | 总股本：7.49亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 668,575,211.14 | 287,337,235.01 | 2,018,333,771.81 | 1,335,156,050.4 |
| 营业收入 | 668,575,211.14 | 287,337,235.01 | 2,018,333,771.81 | 1,335,156,050.4 |
| 二、营业总成本 | 667,394,336.77 | 288,252,886.21 | 1,763,748,341.31 | 1,227,734,251.03 |
| 营业成本 | 507,935,259.42 | 205,132,917.71 | 1,444,560,234.36 | 968,251,629.5 |
| 税金及附加 | 4,317,229.34 | 1,352,112.14 | 8,981,402.37 | 6,894,612.65 |
| 销售费用 | 14,608,733.68 | 6,079,268.59 | 27,881,056.45 | 19,402,507.49 |
| 管理费用 | 134,505,155.96 | 71,784,152.89 | 289,180,575.62 | 236,735,760.07 |
| 研发费用 | 43,446,069.62 | 23,027,883.99 | 92,918,280.66 | 71,085,657.06 |
| 财务费用 | -37,418,111.25 | -19,123,449.11 | -99,773,208.15 | -74,635,915.74 |
| 其中:利息费用 | 776,460.21 | 521,186.18 | 2,448,073.47 | 1,827,953.64 |
| 其中:利息收入 | 41,322,974.41 | 21,160,369.25 | 103,230,766.43 | 82,526,990.66 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 107,019,073.28 | 65,875,504.16 | -127,048,597.78 | -190,401,449.68 |
| 加:投资收益 | 13,135,262.03 | 1,235,855.96 | 36,011,545.69 | 31,620,189.62 |
| 资产处置收益 | -44,025.87 | - | -48,130.43 | -468,673.84 |
| 资产减值损失(新) | -66,010,456.08 | -32,494,609.52 | -66,540,016.67 | -25,480,216.62 |
| 信用减值损失(新) | 5,391,403.55 | 10,411,088.36 | -19,140,159.62 | -11,477,062.92 |
| 其他收益 | 19,183,378.08 | 5,270,400.41 | 26,527,237.43 | 19,124,400.35 |
| 四、营业利润 | 79,855,509.36 | 49,382,588.17 | 104,347,309.12 | -69,661,013.72 |
| 加:营业外收入 | 319,690.6 | 48,408.25 | 223,456.84 | 96,166.74 |
| 减:营业外支出 | 55,626.21 | 47,246.62 | 531,692.34 | 327,422.81 |
| 五、利润总额 | 80,119,573.75 | 49,383,749.8 | 104,039,073.62 | -69,892,269.79 |
| 减:所得税费用 | 19,187,197.37 | 8,264,284.55 | 34,284,009.72 | 4,351,740.15 |
| 六、净利润 | 60,932,376.38 | 41,119,465.25 | 69,755,063.9 | -74,244,009.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 60,932,376.38 | 41,119,465.25 | 69,755,063.9 | -74,244,009.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 60,932,399.37 | 41,119,492.23 | 74,075,384.59 | -70,307,075.11 |
| 少数股东损益 | -22.99 | -26.98 | -4,320,320.69 | -3,936,934.83 |
| 扣除非经常损益后的净利润 | 23,052,174.74 | 25,662,551.81 | 23,573,407.86 | -113,468,202.36 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.05 | 0.1 | -0.09 |
| (二)稀释每股收益 | 0.08 | 0.05 | 0.1 | -0.09 |
| 八、其他综合收益 | -2,334,068.82 | -766,939.36 | -51,041,084.41 | -4,859,185.75 |
| 归属于母公司股东的其他综合收益 | -2,334,068.82 | -766,939.36 | -51,041,084.41 | -4,859,185.75 |
| 九、综合收益总额 | 58,598,307.56 | 40,352,525.89 | 18,713,979.49 | -79,103,195.69 |
| 归属于母公司股东的综合收益总额 | 58,598,330.55 | 40,352,552.87 | 23,034,300.18 | -75,166,260.86 |
| 归属于少数股东的综合收益总额 | -22.99 | -26.98 | -4,320,320.69 | -3,936,934.83 |
| 公告日期 | 2025-08-27 | 2025-04-29 | 2025-03-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |